ONCS: company's electroporation tech is lisensed from INO. Hopefully the phase 2 results will show the same promise as the recent INO press release.
28 million dollar valuation for ONCS should correct nicely if phase 2 results show similar potential to INO.
Wish the company had been a littler less vague about the release date for these results. Hard to have a run-up if people don't know the exact date for news.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.